GH vs. VCYT, RDNT, VRDN, FLGT, NTRA, TMDX, GDRX, AMED, PACB, and GLPG
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), RadNet (RDNT), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), Natera (NTRA), TransMedics Group (TMDX), GoodRx (GDRX), Amedisys (AMED), Pacific Biosciences of California (PACB), and Galapagos (GLPG). These companies are all part of the "medical" sector.
Guardant Health vs.
Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
In the previous week, Guardant Health and Guardant Health both had 2 articles in the media. Guardant Health's average media sentiment score of 1.43 beat Veracyte's score of 0.46 indicating that Guardant Health is being referred to more favorably in the media.
90.4% of Guardant Health shares are owned by institutional investors. 5.9% of Guardant Health shares are owned by company insiders. Comparatively, 2.9% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Guardant Health has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Veracyte has a net margin of -12.33% compared to Guardant Health's net margin of -145.61%. Veracyte's return on equity of -3.42% beat Guardant Health's return on equity.
Veracyte has lower revenue, but higher earnings than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
Guardant Health currently has a consensus price target of $57.64, indicating a potential upside of 144.35%. Veracyte has a consensus price target of $30.20, indicating a potential upside of 40.66%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Veracyte.
Veracyte received 175 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 73.26% of users gave Veracyte an outperform vote while only 68.61% of users gave Guardant Health an outperform vote.
Summary
Guardant Health beats Veracyte on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Guardant Health Competitors List